

ASX Announcement

23 September 2024

BCAL SECURES COMMERCIAL LICENSE AGREEMENT WITH SYDNEY BREAST CLINIC

Highlights:

- BCAL has selected the Sydney Breast Clinic (“SBC”) as an initial commercialisation partner for BCAL's innovative breast cancer detection tool
- SBC has been a clinical study partner with BCAL for the past 6 years
- The agreement will facilitate patients of SBC being able to access BCAL’s BREASTEST®
- The agreement is another step forward for BCAL to initiate a soft launch of its test by the end of this calendar year.

BCAL Diagnostics Limited (ASX: BDX) (“BCAL”), a company dedicated to improving the early detection of breast cancer, is pleased to announce that it has entered into a commercial license agreement with Sydney Breast Clinic (SBC), one of Australia's foremost multi-disciplinary breast screening clinics. This partnership marks a significant milestone in BCAL's journey towards the commercialisation of BREASTEST®, its breast cancer screening technology.

Renowned for its commitment to providing women with the highest standard of breast care available, SBC has been an invaluable clinical study partner for BCAL over the past 6 years, generously contributing samples to help BCAL develop and validate BREASTEST®. During this period, SBC clinicians have actively collaborated with the BCAL team on the clinical development of the tool.

Shane Ryan, BCAL Diagnostics CEO commented: *“BCAL Diagnostics is proud to continue our longstanding collaboration with SBC, one of the leading private breast cancer clinics in Australia. This licensing agreement means that SBC will be the first site in Australia to offer our breast test to women when it becomes clinically available.”*

With this agreement, BCAL has strategically focused on securing an initial commercialisation partner to assist in building the clinical validation evidence required for a successful commercial soft launch in this calendar year. Furthermore, BCAL's laboratory is also on track to complete its NATA audit and accreditation in the coming weeks.

Professor Mary Rickard, Medical Director of SBC added: *“This collaboration presents a remarkable opportunity to be at the forefront of breast cancer detection and to partner with BCAL in their mission to improve patient outcomes. We are excited to contribute to the validation and commercialization of this promising technology.”*

The commercial terms of the agreement remain confidential to both parties. The executive chair of BCAL Ms Jayne Shaw, having an economic interest in SBC, absented herself from the negotiation and settlement of this agreement.

This announcement has been approved by the Board for release to the ASX.

ENDS

For further information:

Jayne Shaw

Executive Chair

Jshaw@bcaldiagnostics.com

Shane Ryan

Chief Executive Officer

sryan@bcaldiagnostics.com

Media Enquiries

Ana Luiza Graca Harrop

anah@we-worldwide.com.au

About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating excellent performance independent of breast tissue density. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/>